At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)
In Brief
A Phase 3 clinical trial evaluating Placebo and IBI362 for Obesity Or Overweight. Completed, enrolled 610 participants across 23 sites.
Detailed Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.
Study Details
Timeline
Interventions
Placebo administered subcutaneously (SC) once a week.
IBI362 administered subcutaneously (SC) once a week.